Drug
Gedatolisib clinical trials
Also written PF-05212384 and PKI-587.
- studies test it
- 18
- open now
- 3
- in phase 3
- 2
- first study started
- 2010
Keep track of what changes. Save the gedatolisib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
18 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 9
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 9
Pfizer (5) · Celcuity Inc (4) · Dana-Farber Cancer Institute (2) · Kari Wisinski (1) · Kathy Miller (1) · Cristiana Sessa (1) · Institut Curie (1) · University of Florida (1)
Often tested with
Tested in the same studies.
Palbociclib (5) · Letrozole (3) · Fulvestrant (3) · Paclitaxel (2) · Carboplatin (2) · Talazoparib (1) · Metformin (1) · Darolutamide (1)
Studies
Open first, then newest update. How each study uses gedatolisib is read from its arms, and is right about nine times in ten.
Testing it · 18
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)RecruitingPhase 3Celcuity IncNCT06757634Written as Arm A: Gedatolisib + Palbociclib + Fulvestrant
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT03675893Written as Gedatolisib
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1/2Celcuity IncNCT06190899Written as Gedatolisib
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedPhase 1Dana-Farber Cancer InstituteNCT03065062Written as Gedatolisib
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingPhase 3Celcuity IncNCT05501886Written as Gedatolisib
- PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)TerminatedPhase 2Institut CurieNCT02438761Written as PF-05212384
- Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersActive, not recruitingPhase 1/2Kari WisinskiNCT03911973Written as Gedatolisib
- A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerCompletedPhase 1Celcuity IncNCT02684032Written as Gedatolisib
- Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStatus unknownPhase 1Hoffman OncologyNCT02626507Written as Gedatolisib
- An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast CancerCompletedPhase 1Kathy MillerNCT03243331Written as Gedatolisib
- Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")WithdrawnPhase 1/2Abramson Cancer Center at Penn MedicineNCT03400254Written as Gedatolisib
- Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)TerminatedPhase 1/2University of FloridaNCT02920450Written as Gedatolisib
- Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid TumorCompletedPhase 1Cristiana SessaNCT02069158Written as PF-05212384
- A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal CancerTerminatedPhase 2PfizerNCT01925274Written as PF-05212384
- A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial CancerTerminatedPhase 2PfizerNCT01420081Written as PF-05212384
- Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid TumorsCompletedPhase 1PfizerNCT00940498Written as PF-05212384 (also known as PKI-587)
- A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal CancerTerminatedPhase 1/2PfizerNCT01937715Written as PF-05212384
- Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male VolunteersCompletedPhase 1PfizerNCT02142920Written as PF-05212384
Given in every arm · 2 — gedatolisib is usual care beside what is tested
- A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)CompletedPhase 1PfizerNCT01920061Written as PF-05212384 (gedatolisib)
- Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced CancerTerminatedPhase 1PfizerNCT01347866Written as PF-05212384
Codes
What other systems call gedatolisib · ClinicalTrials.gg INT005609
- MeSH (NLM) C549060gedatolisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 96265TNH2RGEDATOLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27077788gedatolisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91732GedatolisibOne source FDA
- DrugBank DB11896One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549060 | gedatolisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 96265TNH2R | GEDATOLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27077788 | gedatolisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91732 | Gedatolisib | One source FDA |
| DrugBank | DB11896 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.